Corrigendum to "Association of Nuclear Factor-Erythroid 2-Related Factor 2, Thioredoxin Interacting Protein, and Heme Oxygenase-1 Gene Polymorphisms with Diabetes and Obesity in Mexican Patients".

[This corrects the article DOI: 10.1155/2016/7367641.].

In the article titled “Association of Nuclear Factor-Erythroid 2-Related Factor 2, Thioredoxin Interacting Protein, and Heme Oxygenase-1 Gene Polymorphisms with Diabetes and Obesity in Mexican Patients,” [1] typing errors were found after subsequent analyses of the entire dataset. These issues were raised to the attention of the original authors by Drs. Meza-Espinoza, Leal-Ugarte, and Peralta-Leal of the Universidad Autónoma de Tamaulipas. The allelic frequencies were added and the corrected data are shown in italics in Tables 2, 3, and 4.

Table 2

Genotype and allele frequencies of the polymorphisms studied in diabetic patients and controls.

Gene/polymorphism	Genotypes	Diabetes	Controls	OR (95% CI)	P	P of HWE
	Alleles	n (%)	n (%)
TXNIP rs7211	CC	345 (55.4)	528 (54.5)	Reference		0.880
	CT	239 (38.4)	376 (38.8)	0.97 (0.78–1.2)	0.798
	TT	39 (6.2)	65 (6.7)	0.92 (0.60–1.39)	0.690
	C	939 (74.6)	1432 (73.9)	Reference
	T	317 (25.4)	506 (26.1)	0.966 (1.82–1.37)	0.674
NQO1 rs1800566	CC	216 (34.7)	327 (33)	Reference		0.406
	CT	288 (46.2)	483 (48.6)	0.90 (0.7–1.1)	0.373
	TT	119 (19.1)	183 (18.4)	0.98 (0.7–1.3)	0.915
	C	720 (57.8)	1137 (57.25)	Reference
	T	526 (42.2)	849 (42.75)	0.98 (0.85–1.13)	0.765
HMOX-1 rs2071749	AA	269 (43.8)	413 (43.2)	Reference		0.625
	AG	267 (43.5)	417 (43.6)	0.98 (0.79–1.2)	0.877
	GG	78 (12.7)	126 (13.2)	0.95 (0.69–1.3)	0.757
	A	805 (65.5)	1243 (65)	Reference
	G	423 (34.5)	669 (35)	0.97 (0.84–1.13)	0.755
NRF2 rs2364723	CC	210 (33.6)	301 (30.3)	Reference		0.092
	CG	286 (45.7)	471 (47.5)	0.87 (0.7–1.1)	0.236
	GG	129 (20.6)	220 (22.2)	0.84 (0.63–1.1)	0.223
	C	706 (56.5)	1073 (54)	Reference
	G	544 (43.5)	911 (46)	0.91 (0.79–1.05)	0.182
NRF2 rs6721961	CC	407 (65.3)	618 (62.5)	Reference		0.281
	CA	189 (30.4)	317 (32)	0.90 (0.7–1.1)	0.374
	AA	27 (4.3)	54 (5.5)	0.76 (0.5–1.2)	0.259
	C	1003 (80.5)	1553 (78.5)	Reference
	A	243 (19.5)	425 (21.5)	0.88 (0.74–1.05)	0.176

CI, confidence interval; HWE, Hardy-Weinberg equilibrium; HMOX-1, heme oxygenase 1; NQO1, NAD(P)H quinone oxidoreductase 1; NRF2, nuclear factor-erythroid 2- (NF-E2-) related factor 2; OR, odds ratio; and TXNIP, thioredoxin-interacting protein.

Table 3

Genotype and allele frequencies of the polymorphisms studied in obese and nonobese subjects.

Gene/polymorphism	Genotype	Obesity	No obesity	OR (95% CI)	P
	Alleles	n (%)	n (%)
TRXNIP rs7211	CC	350 (56.6)	523 (53.7)	Reference
	CT	239 (38.7)	376 (38.6)	0.95 (0.77–1.17)	0.633
	TT	29 (4.7)	75 (7.7)	0.57 (0.37–0.9)	0.017
	C	239 (76)	1422 (73)	Reference
	T	297 (24)	526 (27)	0.85 (0.72–1)	0.061
NQO1 rs1800566	CC	212 (34.2)	331 (33.3)	Reference
	CT	302 (48.8)	469 (47)	1 (0.8–1.25)	0.963
	TT	106 (17)	196 (19.7)	0.84 (0.6–1.1)	0.257
	C	726 (58.5)	1131 (56.8)	Reference
	T	514 (41.5)	561 (43.2)	0.93 (0.8–1.07)	0.322
HMOX-1 rs2071749	AA	261 (40)	419 (45.7)	Reference
	AG	305 (46.9)	378 (41.3)	1.3 (1–1.6)	0.019
	GG	85 (13.1)	119 (13)	1.1 (0.8–1.5)	0.399
	G	827 (63.5)	1216 (66.4)	Reference
	A	475 (36.5)	616 (36.6)	1.13 (0.97–1.31)	0.097
NRF2 rs2364723	CC	194 (31)	317 (32)	Reference
	CG	300 (48)	457 (46)	1.1 (0.85–1.35)	0.551
	GG	131 (21)	218 (22)	0.98 (0.7–1.3)	0.899
	C	688 (55)	1091 (55)	Reference
	G	562 (45)	893 (45)	0.99 (0.86–1.15)	0.699
NRF2 rs6721961	CC	390 (63.1)	635 (63.9)	Reference
	CA	195 (31.6)	311 (31.3)	1 (0.8–1.3)	0.853
	AA	33 (5.3)	48 (4.8)	1.1 (0.7–1.7)	0.631
	C	975 (78.9)	1581 (79.5)	Reference
	A	261 (21.1)	407 (20.5)	1.04 (0.87–1.23)	0.661

TXNIP, thioredoxin-interacting protein; NQO1, NAD(P)H quinone oxidoreductase 1; HMOX-1, heme oxygenase 1; NRF2, nuclear factor-erythroid 2- (NF-E2-) related factor 2.

Table 4

Genotype frequency of the rs7211 polymorphism in subjects without diabetes and women.

	Obese	Nonobese	Crude OR (95% CI)	P	Adjusteda OR (95% CI)	P
Nondiabetic
CC	189 (56.6)	339 (53.4)	Reference		Reference
CT	133 (39.8)	243 (38.3)	0.98 (0.75–1.3)	0.896	1 (0.77–1.4)	0.863
TT	12 (3.6)	53 (8.3)	0.4 (0.21–0.77)	0.007	0.3 (0.15–0.7)	0.003
CC + CT = 0 versus TT = 1	322 (96.4)	582 (91.5)	0.4 (0.21–0.76)	0.006	0.39 (0.18–0.8)	0.014
Women
CC	197 (59)	259 (51)	Reference		Reference
CT	118 (36)	203 (40)	0.7 (0.6–1)	0.072	0.9 (0.6–1.2)	0.418
TT	17 (5)	47 (9)	0.5 (0.26–0.85)	0.013	0.5 (0.25–0.96)	0.04
CT + TT	135 (41)	250 (49)	0.70 (0.5–0.9)	0.016	0.7 (0.5–0.96)	0.028

CI, confidence interval; OR, odds ratio.

aObesity in logistic regression was adjusted by age, gender (except in women model), glucose, triglycerides, LDL-C, and HDL-C levels.

It is important to remark that the model (recessive for allele T, Table 4) was calculated taking in count that CC + CT = 0. When CC is considered as the risk allele the OR increases to 2.4 (CI: 1.28–4.64, P = 0.006) under a dominant model (CC + CT = 1 versus TT = 0). This reveals that the TT genotype in this study shows a protective factor against obesity and the genotype CC could be considered as the risk factor for obesity, as was stated in the original article.

The last paragraph of Section 3 should be “CC carriers had higher glucose levels in comparison with CA + AA carriers when genotype was compared as dominant model.”

Finally, in Section 4 (Discussion) when Wang et al. [7] is cited, the correct statement is the following:

“Individuals with CC genotype had lower total antioxidant capacity, glutathione levels, superoxide dismutase, catalase, and glutathione peroxidase activities as well as lower homeostasis model assessment of β-cell function index (HOMA-β) in comparison with individuals with the AA genotype.”